Genitourinary Syndrome of Menopause

GSM is a clinical syndrome encompassing vulvovaginal and lower urinary tract symptoms associated with estrogen deficiency; the symptom cluster may include dryness, burning, irritation, dyspareunia, dysuria, urgency, and recurrent urinary tract infections. ScienceDirect+1ScienceDirectCO2-Laser therapy and Genitourinary Syndrome of Menopause: A Systematic Review and Meta-AnalysisWileyLaser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial - Serquiz - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library At the first visit, document the dominant domain—penetrative pain, vulvar burning, urinary urgency/dysuria, recurrent culture-confirmed UTI, or mixed symptoms—because treatment response and competing diagnoses differ by domain.

Perform a focused vulvar, vaginal, and pelvic examination when symptoms are new, severe, refractory, or accompanied by bleeding, discharge, focal pain, or a visible lesion. A lesion, erosive process, marked architectural change, purulent discharge, abnormal uterine bleeding, or a palpable pelvic mass should redirect evaluation toward vulvar dermatosis or neoplasia, vaginitis or sexually transmitted infection, cervical/endometrial pathology, pelvic floor dysfunction, or bladder disease rather than escalation of GSM therapy.

For dysuria, urgency, or recurrent UTI, obtain urinalysis and urine culture when infection is clinically plausible; do not label persistent urinary symptoms as estrogen deficiency after a negative or discordant infectious evaluation without reassessing the pelvic examination and bladder differential. Urinary complaints during menopause have multiple contributors and are not all attributable solely to estrogen deficiency. WileyWileyMenopausal hormone therapy and comprehensive ...

For mild symptoms or for patients avoiding hormones, use vaginal moisturizers on a regular schedule and lubricants with sexual activity. In breast cancer survivors, these nonhormonal options are generally the initial approach, but their benefit is typically mild and short term. WileyWileyLaser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial - Serquiz - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library Reassess the specific symptom driving distress—dyspareunia, dryness, burning, or urinary symptoms—rather than continuing an ineffective product indefinitely.

For persistent bothersome GSM, low-dose vaginal estrogen is an effective local option delivered as cream, tablet, insert, suppository, or local silicone ring. jacc+1jaccMenopause Hormone Therapy After Spontaneous Coronary Artery Dissection: A Gap in the LiteraturejaccImproving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife Low-dose vaginal estrogen is minimally absorbed and does not require concomitant progesterone in patients with an intact uterus. jaccjaccImproving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife Verify that a vaginal ring is a local low-dose product rather than a systemically delivering ring before prescribing. jaccjaccMenopause Hormone Therapy After Spontaneous Coronary Artery Dissection: A Gap in the Literature

Use systemic menopausal hormone therapy only when there is a separate systemic indication, such as vasomotor symptoms or prevention of bone loss and fracture risk, and then account for uterine status and cardiovascular/thrombotic risk. jaccjaccImproving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife Estrogen alone in a patient with an intact uterus increases endometrial hyperplasia and cancer risk and should be paired with a progestin or an endometrial-protective SERM strategy when systemic therapy is used. jaccjaccImproving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife Oral formulations are associated with hypertriglyceridemia, venous thromboembolism, and elevated high-sensitivity C-reactive protein; observational data suggest transdermal estrogen may carry less venous thromboembolism and stroke risk than oral estrogen. jaccjaccImproving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife

Vaginal prasterone (dehydroepiandrosterone) is an alternative pharmacologic option when nonhormonal products or vaginal estrogen are ineffective or unsuitable. WileyWileyMenopausal hormone therapy and comprehensive ... It may be particularly relevant when a patient cannot tolerate a local estrogen formulation, but treatment selection in cancer survivors remains individualized because robust safety data in gynecologic cancer survivors are limited. WileyWileyMenopausal hormone therapy and comprehensive ...

Oral ospemifene is a selective estrogen receptor modulator and the only FDA-approved oral treatment for GSM. WileyWileyGenitourinary Syndrome of Menopause - Marino - 2021 It may be useful when local therapy cannot be tolerated or accessed, including situations such as post-radiation vaginal stenosis, but its systemic exposure and limited safety data in gynecologic cancer survivors require a different risk discussion from low-dose vaginal estrogen. WileyWileyMenopausal hormone therapy and comprehensive ...

Avoid presenting energy-based vaginal devices as equivalent to established medical therapies. CO2 laser and radiofrequency have been studied, including randomized sham-controlled trials, but evidence remains uncertain; in breast cancer survivor trials, pain during treatment was common and one trial reported adverse effects in 37% of laser-treated participants versus 27% of sham-treated participants, without differences in incidence or severity. Wiley+1WileyLaser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial - Serquiz - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online LibraryauajournalsThe AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause

Breast cancer survivors often have more severe vulvovaginal atrophy and symptom burden than postmenopausal women without breast cancer; chemotherapy, tamoxifen, and aromatase inhibitors can worsen the hypoestrogenic genital environment. WileyWileyLaser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial - Serquiz - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library Ask whether symptoms threaten sexual function, sleep, urinary health, or adherence to adjuvant endocrine therapy, because the severity of functional impact determines whether limited nonhormonal relief is acceptable.

Begin with nonhormonal moisturizers and lubricants in breast cancer survivors. WileyWileyLaser and radiofrequency for treating genitourinary syndrome of menopause in breast cancer survivors: A systematic review of randomized controlled trial - Serquiz - 2026 - International Journal of Gynecology & Obstetrics - Wiley Online Library For persistent moderate-to-severe GSM, vaginal estrogen may be considered after individualized assessment and, when appropriate, discussion with the oncology team; decisions should account for cancer type, tumor biology, current endocrine therapy, symptom severity, and patient priorities. BMJ+1BMJa randomised clinical trial protocol comparing multimodWileyMenopausal hormone therapy and comprehensive ...

Do not extrapolate the low systemic absorption of local therapy to systemic menopausal hormone therapy. In patients with an intact uterus, systemic estrogen requires endometrial protection; oral systemic formulations also carry first-pass-associated hypertriglyceridemia and venous thromboembolism tradeoffs. jaccjaccImproving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife In patients with prior spontaneous coronary artery dissection, reassess the indication for systemic hormone therapy and discontinue it unless there is a compelling reason to continue; recurrent GSM after stopping systemic therapy can prompt coordinated consideration of local treatment. AHA JournalsAHA JournalsSpontaneous Coronary Artery Dissection: Current State of ...

At follow-up, measure the outcome that prompted treatment: pain with penetration, dryness/burning, urinary urgency or dysuria, frequency of culture-confirmed UTI, and ability to continue cancer-directed endocrine therapy. For urinary presentations, improvement with localized estrogen supports a GSM contribution, but persistent symptoms still warrant reassessment because urinary symptoms have multifactorial causes. WileyWileyMenopausal hormone therapy and comprehensive ...

Re-examine patients with persistent pain, recurrent bleeding, new discharge, lesion development, or no meaningful benefit after an adequate treatment trial. Nonresponse should trigger reconsideration of vulvar dermatoses, infection, pelvic floor dysfunction, painful bladder conditions, structural disease, medication effects, or malignancy rather than serial empiric treatment changes.

For patients receiving systemic menopausal hormone therapy for an independent indication, reassess route and ongoing indication periodically. Transdermal treatment may be preferable to oral therapy for patients with moderate cardiovascular risk because available observational evidence suggests lower venous thromboembolism and stroke risk, although large randomized comparisons are lacking. jaccjaccImproving Cardiovascular Clinical Competencies for the Menopausal Transition: A Focus on Cardiometabolic Health in Midlife